Skip Navigation


Rheumatology Advance Access originally published online on January 13, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/4/491    most recent
keh082v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Riley, P.
Right arrow Articles by Pilkington, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riley, P.
Right arrow Articles by Pilkington, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 491-496
Rheumatology Vol. 43 No. 4 (c) British Society for Rheumatology 2004; all rights reserved

Clinical

Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety

P. Riley, S. M. Maillard, L. R. Wedderburn, P. Woo, K. J. Murray and C. A. Pilkington

Juvenile Dermatomyositis Research Centre, Institute of Child Health, Great Ormond Street, London, UK

Correspondence to: C. A. Pilkington, Juvenile Dermatomyositis Research Centre, Institute of Child Health, UCL, 30 Guilford Street, London WC1N 1EH, UK. E-mail: C.Pilkington{at}ich.ucl.ac.uk

Objectives. To assess the efficacy and safety of intravenous cyclophosphamide (CYP) used in severe and refractory juvenile dermatomyositis (JDM).

Methods. Retrospective case note review of the outcome of 12 patients.

Results. Assessment at 6 months of therapy in 10 of the 12 patients showed a significant improvement in muscle function as assessed by the Childhood Myositis Assessment Scale (CMAS) (P = 0.012), muscle strength (P = 0.008), global extramuscular disease score (P = 0.008), skin disease severity (P = 0.015) and lactate dehydrogenase (P = 0.028). There were reductions in creatine kinase, alanine aminotransferase, prednisolone dose and ESR, but these did not reach statistical significance. Clinical improvement was maintained after CYP until the most recent follow-up (between 6 months and 7 yr) and no severe side-effects were seen. Reversible complications included lymphopenia, herpes zoster infections and alopecia. The median cumulative dose was 4.6 g/m2 (range 3–9 g/m2). The available evidence suggests that, at the doses required, risks of malignancy, infertility and gonadal failure are low. Two patients with severe treatment-resistant disease died after one dose of CYP, both of whom were ventilated prior to commencement of CYP and were thought to have died as a result of their severe disease process, and too early for clinical benefit to be obtained from the drug.

Conclusions. In this cohort of children with severe and refractory JDM, CYP appeared to have provided major clinical benefit with no evidence of serious toxicity in the short term.

KEY WORDS: Juvenile, Dermatomyositis, Cyclophosphamide, Refractory, Ulcerative, Childhood, Vasculitis, Interstitial lung, Gastrointestinal.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. J. McCann, A. D. Juggins, S. M. Maillard, L. R. Wedderburn, J. E. Davidson, K. J. Murray, C. A. Pilkington, and on behalf of the Juvenile Dermatomyositis Research
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr
Rheumatology, October 1, 2006; 45(10): 1255 - 1260.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.